Medtronic management check
MDT · Health Care · Health Care Equipment · CEO Geoff Martha
Filings as of
Closest peers in Health Care Equipment
- 153ISRGIntuitive Surgical72
- 158ABTAbbott Laboratories72
- 162SYKStryker Corporation71
- 185IDXXIdexx Laboratories69
- 199BSXBoston Scientific68
- 250RVTYRevvity64
- 284RMDResMed63
- 286GEHCGE HealthCare62
- 322STESteris60
- 353BDXBecton Dickinson58
The seven checks
- FlagTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2022
2029thDetail
$100 invested at the start of fiscal 2022 grew to $74, against $97 for the peer group the company picked itself.
- FlagPay moved against returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
203rdDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of -0.59 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Flag477822.4% of net income
What does the CEO cost owners?
$22.9m pay · $5k net income, FY2026
016thDetail
$22.9m of reported pay in fiscal 2026, against $5k of net income.
- WatchCEO stake ≈ 1.2 years of pay
Do they own the stock?
277,866 shares ≈ $26.4m
6 mo: ▲ $0 bought · ▼ $6.5m sold
3840thDetail
The CEO holds 277,866 shares, directly or through trusts (unvested awards not counted): about 1.2 years of pay. Light activity: no buys, $6.5m sold in six months. 3 of 6 sales ran on pre-arranged 10b5-1 plans.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −1.6% a year; flagged above +2%
Stock pay 1.3% of revenue
7062ndDetail
Diluted shares changed -1.6% a year over the last three fiscal years. Stock-based pay was 1.3% of revenue in the latest year.
- Watch12 leadership filings in 3 years
Is leadership stable?
12 filings under 8-K 5.02 in 3 years
CEO: Geoff Martha
6540thDetail
CEO in the pay table: Geoff Martha. 12 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed August 17, 2026.
Pay tied most to Revenue Growth
Other key measuresEPSTotal Shareholder ReturnFree Cash Flow
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2026 | Geoff Martha | $22.9m | $22.5m | $7.3m | $74 | $97 | $5k |
| 2025 | Geoff Martha | $21.2m | $26.1m | $5.6m | $98 | $149 | $5k |
| 2024 | Geoff Martha | $20.1m | $11.1m | $7.6m | $90 | $135 | $4k |
| 2023 | Geoff Martha | $15.4m | $3.3m | $5.4m | $99 | $131 | $4k |
| 2022 | Geoff Martha | $17.9m | $3.0m | $7.6m | $110 | $124 | $5k |
Insiders and the CEO's stakeQuiet
- Chairman and CEO
- Geoffrey Martha
- Shares held
- 277,866
- At that filing's price
- ≈ $26.4m
- Latest Form 4
- Oct 15, 2026
Light activity: no buys, $6.5m sold in six months. 3 of 6 sales ran on pre-arranged 10b5-1 plans.
Open-market trades by officers and directors since May 21, 2026.
- SoldGeoffrey MarthaChairman and CEO · 10b5-1 plan$4.8mOct 15, 2026
- SoldMichael MarinaroEVP, Pres MedSurg and Americas · 10b5-1 plan$1.0mOct 15, 2026
- SoldHarry Skip KiilEVP & President Cardiovascular$476kSep 16, 2026
- SoldMatthew R. WalterSVP, Chief HR Officer · 10b5-1 plan$258kJul 8, 2026
Leadership and governance on file
All 16 filings
- Oct 19, 2026Leadership change8-K 5.02
- May 18, 2026Leadership change8-K 5.02
- Nov 3, 2025Leadership change8-K 5.02
- Aug 19, 2025Leadership change8-K 5.02
- Jun 23, 2025Leadership change8-K 5.02
- May 21, 2025Leadership change8-K 5.02
- Mar 17, 2025Leadership change8-K 5.02
- Jan 21, 2025Leadership change8-K 5.02
- Aug 16, 2024Leadership change8-K/A 5.02
- Jun 26, 2024Leadership change8-K 5.02
- Jun 4, 2024Leadership change8-K 5.02
- Feb 20, 2024Leadership change8-K 5.02
- Oct 23, 2023Leadership change8-K 5.02
- Jun 26, 2023Leadership change8-K 5.02
- Jun 27, 2022Leadership change8-K 5.02
- Dec 16, 2021Leadership change8-K 5.02
Latest shareholder vote results: Oct 19, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $27.5bn returned to owners in buybacks and dividends, 125319110% of net income, and $2.0bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $31.7bn | $31.2bn | $32.4bn | $33.5bn | $36.4bn |
| Net income | $5k | $4k | $4k | $5k | $5k |
| Stock-based pay | $359.0m | $355.0m | $393.0m | $429.0m | $457.0m |
| Buybacks | $2.5bn | $645.0m | $2.1bn | $3.2bn | $1.0bn |
| Dividends | $3.4bn | $3.6bn | $3.7bn | $3.6bn | $3.6bn |
| Diluted shares | 1351m | 1333m | 1330m | 1290m | 1288m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.